GIGABYTE
14.12.2022 15:01:34 CET | Business Wire | Press release
GIGABYTE, a leading brand of computer innovations and key player in the tech industry, resumes its strong presence at the upcoming CES (#9119 LVCC North Hall). From January 5th to 8th, GIGABYTE will exhibit its HPC products and total solutions, demonstrating the full breadth of ‘Power of Computing’ and its impact on shaping the technology landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005086/en/
Driving Technology Towards Net Zero, GIGABYTE HPC Solutions Rally ‘Power of Computing’ at CES (Photo: Business Wire)
GIGABYTE is addressing a serious topic that concerns the tech industry on a global scale with its HPC solutions. The data centers in the world account for as much carbon emission as the entire aviation industry while technology continues progressing rapidly in the direction where more computing performance is required to keep up with the innovations. This challenge of balancing computing demand vs carbon footprint can be overcome by optimizing data centers' operation stability and power usage effectiveness using advanced cooling solutions, which is one of the highlighted sections in GIGABYTE's booth. The section features a walkthrough of the mainstream cooling solutions and a display of server products designed to fit in air, direct-liquid, and immersion cooling.
GIGABYTE invested in immersion cooling technology early, and has a monumental breakthrough this year as it released its own-designed immersion cooling tanks that comply with both EIA and OCP specifications. The investment in immersion cooling has come to fruition as GIGABYTE's expertise in the technology was trusted by the world's leading IC foundry giant, which in turn, garnered GIGABYTE's experience and products to propel its advanced process and pursue its ESG leadership and influence.
Vehicle tech is thriving as it leverages the power of computing to helm artificial intelligence and communications, therefore paving way for safer driving and smarter traffic. With extensive experience in developing ADCU (Autonomous Driving Control Unit) and ADAS DCU (Domain Control Unit), GIGABYTE provides the automotive industry with high-performance Zonal Integrated DCUs and decision-making control hosts, which are built with a centralized architecture and can be integrated into various requirements and design concepts, lowering vehicle production costs.
GIGABYTE invited other companies of key components and strategic partnership to exhibit a comprehensive demonstration of a smart car, illustrating the computers' capacity to receive information from multiple signals and process the information in real-time to prompt critical and accurate corresponding commands.
The annual CES remains a landmark event for thought leaders and influencers to come together and pivot future tech evolution. The ‘Power of Computing’ is becoming a prevalent resource that pushes the pedal of the 21st century digital transformation. GIGABYTE brought its data center expertise and industry know-how, from HPC servers, workstations to personal computers, and AI solutions from development platforms to self-driving cars, to empower users from enterprises to individuals to expand their business endeavors and personal visions. GIGABYTE is excited to welcome attendees to visit its booth to connect and move the future together using ‘Power of Computing’.
Visit GIGABYTE ‘Power of Computing’ event page
More information at https://www.gigabyte.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005086/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom